Zoryve
Total Payments
$5.9M
Transactions
48,172
Doctors
9,750
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5.9M | 48,172 | 9,750 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $3.2M | 1,285 | 55.2% |
| Unspecified | $1.1M | 432 | 19.6% |
| Food and Beverage | $1.1M | 45,396 | 18.7% |
| Travel and Lodging | $368,824 | 1,025 | 6.3% |
| Grant | $7,000 | 1 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,053 | 26 | 0.0% |
| Education | $151.20 | 5 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28.00 | 2 | 0.0% |
Payments by Type
General
$4.7M
47,740 transactions
Research
$1.1M
432 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | $943,841 | 4 |
| A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | $146,907 | 2 |
| A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preceding Studies ARQ-151-301 or ARQ-151-302 | Arcutis Biotherapeutics, Inc. | $53,878 | 1 |
| A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | $4,512 | 0 |
Top Doctors Receiving Payments for Zoryve — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Dermatology | Bloomfield Hills, MI | $40,993 | 32 |
| , MD | Dermatology | Las Vegas, NV | $40,579 | 50 |
| , MD | Dermatology | Voorhees, NJ | $40,094 | 45 |
| , MD | Dermatology | Austin, TX | $39,616 | 21 |
| , MD | Dermatology | San Diego, CA | $39,223 | 57 |
| , M.D | Dermatopathology | Buffalo Grove, IL | $38,161 | 43 |
| , M.D | Dermatology | Mill Creek, WA | $38,151 | 52 |
| , MD | Dermatology | Virginia Beach, VA | $37,707 | 60 |
| , MD | Dermatology | Portsmouth, NH | $36,663 | 40 |
| , D.O | Dermatology | New York, NY | $34,377 | 39 |
| , M.D | Dermatology | Bulverde, TX | $33,907 | 31 |
| , PA-C | Physician Assistant | Irvine, CA | $33,694 | 80 |
| , MD | Dermatology | Columbus, OH | $33,081 | 27 |
| , M.D | Dermatology | Bellaire, TX | $32,012 | 43 |
| , M.D | MOHS-Micrographic Surgery | Bakersfield, CA | $31,287 | 29 |
| , PA-C | Physician Assistant | Dallas, TX | $30,378 | 76 |
| Michael Cameron | Dermatology | New York, NY | $29,407 | 48 |
| , MD | Dermatology | Mc Lean, VA | $29,214 | 64 |
| , M.D | MOHS-Micrographic Surgery | Douglasville, GA | $29,150 | 35 |
| , M.D | Dermatology | Dallas, TX | $28,543 | 58 |
| , DO | Dermatology | Marion, OH | $28,514 | 31 |
| , M.D | Dermatology | Pflugerville, TX | $27,956 | 24 |
| , M.D | Pediatric Dermatology | Houston, TX | $27,416 | 21 |
| , M.D | Dermatology | Itasca, IL | $26,808 | 22 |
| , M.D | Allergy & Immunology | Littleton, CO | $26,475 | 46 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.9M
- Total Doctors 9,750
- Transactions 48,172
About Zoryve
Zoryve is a drug associated with $5.9M in payments to 9,750 healthcare providers, recorded across 48,172 transactions in the CMS Open Payments database. The primary manufacturer is Arcutis Biotherapeutics, Inc..
Payment data is available from 2024 to 2024. In 2024, $5.9M was paid across 48,172 transactions to 9,750 doctors.
The most common payment nature for Zoryve is "Consulting Fee" ($3.2M, 55.2% of total).
Zoryve is associated with 4 research studies, including "A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis" ($943,841).